|
You are here: Home: BCU 6|2002: John F. Robertson, MD, FRCS:
Select publications
Fulvestrant (ICI 182,780; Faslodex®)
Bundred N et al. ICI 182,780 (Faslodex) an estrogen receptor
downregulator, reduces cell turnover index more effectively than
tamoxifen. Proc ASCO 2001;Abstract
1660.
Bundred N, Howell A. Fulvestrant (Faslodex): Current status
in the therapy of breast cancer. Expert Rev Anticancer
Ther 2002;2(2):151-60. Abstract
Cheung KL, Robertson JF. Fulvestrant. Expert
Opin Investig Drugs 2002;11:303-308. Abstract
Curran M, Wiseman L. Fulvestrant. Drugs 2001;61:807-13;
discussion 814. Abstract
Elkak AE, Mokbel K. Pure antiestrogens and breast cancer.
Curr Med Res Opin 2001;17:282-9. Abstract
Erikstein B et al. ICI 182,780 (‘Faslodex’)
250 mg monthly intramuscular (IM) injection shows consistent PK
profile when given as either 1 x 5ml or 2 x 2.5 ml injections in
postmenopausal women with advanced breast cancer (ABC).
Proc ASCO 2001;Abstract
2025.
Gu Z et al. Association of interferon regulatory factor-1,
nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element
binding with acquired resistance to Faslodex (ICI 182,780). Cancer
Res 2002;62(12):3428-37. Abstract
Howell A. Faslodex (ICI 182780). An oestrogen receptor
downregulator. Eur J Cancer 2000;36 Suppl 4:S87-8. Abstract
Howell A. Preliminary experience with pure antiestrogens.
Clin Cancer Res 2001;7:4369s- 4375s;discussion 4411s-4412s.
Abstract
Howell A et al. Comparison of efficacy and tolerability
of fulvestrant (Faslodex) with anastrozole (Arimidex) in post-menopausal
women with advanced breast cancer. Breast Cancer Res Treat
2000;64(1):Abstract 6.
Johnston SR. Fulvestrant (AstraZeneca). Curr
Opin Investig Drugs 2002;3(2):305-12. Abstract
Jones S. Fulvestrant ('Faslodex®') versus anastrozole
('Arimidex®') for the treatment of advanced breast cancer in
postmenopausal women – safety update on the combined analysis
of two multicenter trials. Breast Cancer Res Treat 2001;Abstract
455.
Long BJ et al. The effect of second-line antiestrogen
therapy on breast tumor growth after first-line treatment with the
aromatase inhibitor letrozole: Long-term studies using the intratumoral
aromatase postmenopausal breast cancer model. Clin Cancer
Res 2002;8(7):2378-88. Abstract
Mauriac L. Fulvestrant ('Faslodex®') is effective
in advanced breast cancer in postmenopausal patients with visceral
metastases: Comparison with anastrazole. Breast Cancer
Res Treat 2001;Abstract
452
O’Regan RM et al. Effects of the antiestrogens tamoxifen,
toremifene, and ICI 182,780 on endometrial cancer growth. J
Natl Cancer Inst 1998;90:1552-8. Abstract
Osborne CK. A double-blind randomized trial comparing
the efficacy and tolerability of FaslodexTM (fulvestrant) with ArimidexTM
(anastrozole) in post-menopausal (PM) women with advanced breast
cancer (ABC). Breast Cancer Res Treat 2000;64(1):Abstract
7.
Osborne CK et al. Selective estrogen receptor modulators:
Structure, function and clinical use. J Clin Oncol 2000;18(17):3172-3186.
Abstract
Parker LM et al. Greater duration of response in patients
receiving fulvestrant (‘Faslodex’) compared with those
receiving anastrozole (‘Arimidex’). Proc ASCO
2002;Abstract
160.
Robertson JF. Estrogen receptor downregulators: New antihormonal
therapy for advanced breast cancer. Clin Ther 2002;24 Suppl
A:A17-30. Abstract
Robertson JFR. A comparison of the single-dose pharmacokinetics
(PK) of ‘Faslodex’ (fulvestrant) 250 mg when given as
either a one x 5-ml intramuscular (IM) injection or two x 2.5-ml
injections in postmenopausal (PM) women with advanced breast cancer
(ABC). Breast Cancer Res Treat 2000;Abstract 172.
Rosenberg Z and RS et al. Is ICI 182,780 an antiprogestin
in addition to being an antiestrogen? Breast Cancer Res
Treat 2000;60:1-8. Abstract
Vergote I. Evidence of continued sensitivity to endocrine
agents in postmenopausal women with advanced breast cancer progressing
on fulvestrant ('Faslodex®') treatment. Breast Cancer
Res Treat 2001;Abstract
446.
Wardley AM. Fulvestrant: A review of its development,
pre-clinical and clinical data. Int J Clin Pract 2002;56(4):305-9.
Abstract
|
